Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
Kaehler KC, Blome C, Forschner A, Gutzmer R, Haalck T, Heinzerling L, Kornek T, Livingstone E, Loquai C, Maul LV, Lang BM, Schadendorf D, Stade B, Terheyden P, Utikal J, Wagner T, Hauschild A, Garbe C, Augustin M. Kaehler KC, et al. Among authors: maul lv. Medicine (Baltimore). 2016 Nov;95(46):e5375. doi: 10.1097/MD.0000000000005375. Medicine (Baltimore). 2016. PMID: 27861370 Free PMC article.
Ephedrine-induced maculopapular rash.
Maul LV, Streit M, Grabbe J. Maul LV, et al. Contact Dermatitis. 2018 Sep;79(3):193-194. doi: 10.1111/cod.13027. Epub 2018 May 15. Contact Dermatitis. 2018. PMID: 29766529 No abstract available.
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial).
Kähler KC, Hüning S, Nashan D, Meiss F, Rafei-Shamsabadi DA, Rissmann H, Colapietro C, Livingstone E, Maul LV, Heppt M, Hassel JC, Gutzmer R, Loquai C, Heinzerling L, Sachse MM, Bohne AS, Moysig L, Peters W, Rusch J, Blome C. Kähler KC, et al. Among authors: maul lv. J Cancer Res Clin Oncol. 2023 Oct;149(13):11705-11718. doi: 10.1007/s00432-023-05027-z. Epub 2023 Jul 5. J Cancer Res Clin Oncol. 2023. PMID: 37405475 Free PMC article.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, Höller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul LV, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppt MV, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C. Schumann K, et al. Among authors: maul lv. J Eur Acad Dermatol Venereol. 2023 May;37(5):894-906. doi: 10.1111/jdv.18779. Epub 2022 Dec 12. J Eur Acad Dermatol Venereol. 2023. PMID: 36433688
54 results